|
🐜
|
The landscape of cancer genes and mutational processes in breast cancer
68 auth.
P. Stephens,
P. Tarpey,
H. Davies,
P. Van Loo,
C. Greenman,
D. Wedge,
S. Nik-Zainal,
Sancha Martin,
I. Varela,
G. Bignell,
L. Yates,
E. Papaemmanuil,
D. Beare,
A. Butler,
Angela M. Cheverton,
...
John Gamble,
Jonathan Hinton,
Mingming Jia,
Alagurevathi Jayakumar,
David Jones,
Calli Latimer,
K. Lau,
Stuart Mclaren,
D. Mcbride,
A. Menzies,
L. Mudie,
K. Raine,
R. Rad,
M. Spencer Chapman,
J. Teague,
D. Easton,
A. Langerød,
Rolf Ellen Bjorn Torill Lars Karesen Schlichting Naume Sauer Ottestad,
R. Kåresen,
E. Schlichting,
B. Naume,
Torill Sauer,
L. Ottestad,
M. Lee,
Chen-Yang Shen,
Benita Tan Kiat Tee,
Bernice Wong Huimin,
A. Broeks,
A. Vargas,
G. Turashvili,
J. Martens,
Aquila Fatima,
P. Miron,
S. Chin,
G. Thomas,
S. Boyault,
O. Mariani,
S. Lakhani,
M. J. van de Vijver,
Laura van ’t Veer,
J. Foekens,
C. Desmedt,
C. Sotiriou,
A. Tutt,
C. Caldas,
J. Reis-Filho,
S. Aparicio,
A. Salomon,
A. Børresen-Dale,
A. Richardson,
P. Campbell,
P. Futreal,
M. Stratton
|
10 |
2012 |
10
🐜
|
|
🐜
|
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.
17 auth.
T. Powles,
Sandy Paterson,
J. Kanis,
E. McCloskey,
S. Ashley,
A. Tidy,
Kirsi Rosenqvist,
I. Smith,
L. Ottestad,
S. Legault,
...
M. Pajunen,
A. Nevantaus,
E. Männistö,
A. Suovuori,
S. Atula,
J. Nevalainen,
L. Pylkkänen
|
8 |
2002 |
8
🐜
|
|
🐜
|
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
8 auth.
J. Geisler,
N. King,
M. Dowsett,
L. Ottestad,
S. Lundgren,
P. Walton,
...
P. O. Kormeset,
P. Lønning
|
8 |
1996 |
8
🐜
|
|
🐜
|
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
10 auth.
T. Powles,
A. Paterson,
E. McCloskey,
P. Schein,
B. Scheffler,
A. Tidy,
...
S. Ashley,
I. Smith,
L. Ottestad,
J. Kanis
|
7 |
2006 |
7
🐜
|
|
🐜
|
Screening for germ line TP53 mutations in breast cancer patients.
14 auth.
A. Børresen,
T. I. Andersen,
J. Garber,
Noële Barbier-Piraux,
Noële Barbier-Piraux,
S. Thorlacius,
J. Eyfjord,
L. Ottestad,
B. Smith-Sørensen,
E. Hovig,
...
D. Malkin,
D. Malkin,
S. Friend,
S. Friend
|
7 |
1992 |
7
🐜
|
|
🐬
|
Prognostic significance of TP53 alterations in breast carcinoma.
T. Andersen,
R. Holm,
J. Nesland,
Kristen R. Heimdal,
L. Ottestad,
A. Børresen
|
7 |
1993 |
7
🐬
|
|
🐜
|
Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer
30 auth.
Adam A. Margolin,
E. Bilal,
Erich Huang,
Thea C. Norman,
L. Ottestad,
B. Mecham,
Benjamin A. Sauerwine,
M. Kellen,
L. Mangravite,
Matthew D Furia,
H. K. Vollan,
O. Rueda,
J. Guinney,
N. Deflaux,
B. Hoff,
...
Xavier Schildwachter,
H. Russnes,
Daehoon Park,
V. O. Vang,
Tyler Pirtle,
Lamia Youseff,
C. Citro,
C. Curtis,
V. Kristensen,
J. Hellerstein,
S. Friend,
G. Stolovitzky,
S. Aparicio,
C. Caldas,
A. Børresen-Dale
|
6 |
2013 |
6
🐜
|
|
🐜
|
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
7 auth.
J. Geisler,
S. Detre,
H. Berntsen,
L. Ottestad,
B. Lindtjørn,
M. Dowsett,
...
P. Lønning
|
6 |
2001 |
6
🐜
|
|
🐢
|
The effect of pre-morbid height and weight on the survival of breast cancer patients.
S. Tretli,
Tor Haldorsen,
L. Ottestad
|
6 |
1990 |
6
🐢
|
|
🐜
|
Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas
7 auth.
T. I. Andersen,
A. Gaustad,
A. Børresen,
G. Farrants,
J. Nesland,
L. Ottestad,
...
K. Tveit
|
6 |
1992 |
6
🐜
|
|
🐜
|
Loss of heterozygosity at 11q23.1 in breast carcinomas: Indication for involvement of a gene distal and close to ATM
9 auth.
K. Laake,
Åse Ødegård,
T. I. Andersen,
I. Bukholm,
R. Kåresen,
J. Nesland,
...
L. Ottestad,
Y. Shiloh,
A. Børresen-Dale
|
6 |
1997 |
6
🐜
|
